| Name | Title | Contact Details |
|---|
Lawrence Pharmaceuticals is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Afecta Pharmaceuticals is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine, and supplies diagnostic reagents in the Australasia region. Seqirus cold-chain logistics business ensures the integrity of CSL products, as well as those of our customers, as they are safely delivered across Australia.
At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.
Elligo Health Research helps speed new therapies to market by providing large numbers of patients and clinicians the opportunity to participate in clinical research. Elligo enables rapid and effective clinical trial enrollment and facilitates the study site operations so that clinicians can focus on their research. Our unique direct to patient model allows us to streamline patient identification and qualification, site activation, patient enrollment, study initiation and study conclusion for more efficient and cost-effective trials.